Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women

Abstract Context Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. Objective The objective was to evaluate the effects of elagoli...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2020-03, Vol.105 (3), p.821-832
Main Authors: Archer, David F, Ng, Juki, Chwalisz, Kristof, Chiu, Yi-Lin, Feinberg, Eve C, Miller, Charles E, Feldman, Robert A, Klein, Cheri E
Format: Article
Language:English
Subjects:
17β-Estradiol
Abnormalities
Acetic acid
Contraception
Dosage
Dose-response relationship (Biochemistry)
Endometriosis
Endometrium
Fibroids
Gonadotropin-releasing hormone
Gonadotropins
Health aspects
Hormones, Sex
Luteinizing hormone
Menstruation
Oral administration
Ovaries
Ovulation
Pituitary (anterior)
Progesterone
Sex hormones
Ultrasound
Uterus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Context Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. Objective The objective was to evaluate the effects of elagolix on ovulation and ovarian sex hormones. Design and Setting This was a randomized, open-label, multicenter study. Participants Participants were healthy ovulatory women aged 18 to 40 years. Interventions Elagolix was administered orally for 3 continuous 28-day dosing intervals at 100 to 200 mg once daily (QD), 100 to 300 mg twice daily (BID), and 300 mg BID plus estradiol/norethindrone acetate (E2/NETA) 1/0.5 mg QD. Main Outcome Measures The main outcomes measures were ovulation rates measured by transvaginal ultrasound, progesterone concentrations, and hormone suppression. Results Elagolix suppressed ovulation in a dose-dependent manner. The percentage of women who ovulated was highest at 100 mg QD (78%), intermediate at 150 and 200 mg QD and 100 mg BID (47%–57%), and lowest at 200 and 300 mg BID (32% and 27%, respectively). Addition of E2/NETA to elagolix 300 mg BID further suppressed the ovulation rate to 10%. Elagolix also suppressed luteinizing hormone and follicle stimulating hormone in a dose-dependent manner, leading to dose-dependent suppression of estradiol and progesterone. Elagolix had no effect on serum biomarker of ovarian reserve, and reduced endometrial thickness compared to the screening cycle. Conclusion Women being treated with elagolix may ovulate and should use effective methods of contraception. The rate of ovulation was lowest with elagolix 300 mg BID plus E2/NETA 1/0.5 mg QD.
ISSN:0021-972X
1945-7197
DOI:10.1210/clinem/dgz086